Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Prostate cancer is the most common non-skin cancer among men, often detected after an elevated prostate-specific antigen PSA blood test. Many men with elevated PSA do not have harmful cancer, leading to potentially unnecessary MRI scans and biopsies. This trial evaluates whether machine learning risk calculators can detect clinically significant prostate cancer as effectively as current MRI-based methods while reducing unnecessary procedures and anxiety. Participants will undergo risk stratification using the European Randomised Study of Screening for Prostate Cancer risk calculators to decide who needs further MRI scans and biopsies. This approach is compared to the current practice of performing MRI for all men with suspicious PSA levels. The study examines if risk stratification can safely reduce the number of MRIs and biopsies needed for diagnosis. Men in the study will be monitored during the initial diagnostic work-up, which lasts up to six weeks, with assessments including detection of clinically significant and insignificant prostate cancer and perilesional biopsy results. Follow-up will occur one year after inclusion to evaluate the number of biopsies and MRIs performed, quality of life related to biopsy decisions, and cost-effectiveness of the risk stratification approach.